Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 3Phase 1/2 3

Status

Active not recruiting 2Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Non-Hodgkin 6Lymphoma, B-Cell 5Recurrence 4Burkitt Lymphoma 4Neoplasm, Residual 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma 3Leukemia, Myeloid, Acute 3Leukemia 3Multiple Myeloma 2Lymphoma, Mantle-Cell 2Leukemia, Lymphocytic, Chronic, B-Cell 2Glioma 2Glioblastoma 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Stomach Neoplasms 1Solid Tumors 1Simpson-Golabi-Behmel syndrome 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Effusion, Malignant 1Platinum-Resistant Ovarian Carcinoma 1Pancreatic Neoplasms 1

Interventions

Cyclophosphamide 48Filgrastim 21fludarabine phosphate 19Rituximab 19Etoposide 19Peripheral Blood Stem Cell Transplantation 17fludarabine 16Prednisone 16Vincristine 15Cytarabine 12Doxorubicin 11blinatumomab 8Methotrexate 8Dexamethasone 8Cyclosporine 8Bortezomib 8venetoclax 7Vorinostat 7Paclitaxel 7Melphalan 7Lenalidomide 7Calcium Dobesilate 7Biopsy 7Specimen Handling 6Radiotherapy 6Indium 6tanespimycin 5aldesleukin 5Tacrolimus 5Inotuzumab Ozogamicin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Burkitt Lymphoma × Immunotherapy, Adoptive × Clear all
NCT04545762 2026-01-14

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

University of California, San Francisco

Phase 1 Recruiting
36 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03233854 2025-11-18

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

Stanford University

Phase 1 Active not recruiting
56 enrolled
Lymphoid

Burkitt Lymphoma, Neoplasm, Residual

NCT03241940 2025-06-29

Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies

Stanford University

Phase 1 Active not recruiting
33 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07043218 2025-06-29

A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Shanghai Tongji Hospital, Tongji University School of Medicine

Phase 1 Not yet recruiting
36 enrolled
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡